Skip to Content Facebook Feature Image

SJM Showcases Diverse Offerings in Bangkok Product Seminar

Business

SJM Showcases Diverse Offerings in Bangkok Product Seminar
Business

Business

SJM Showcases Diverse Offerings in Bangkok Product Seminar

2024-09-03 00:41 Last Updated At:01:05

Reinforcing Macau's Unique "Tourism+" Advantage

MACAU, Sept. 2, 2024 /PRNewswire/ -- As part of its ongoing efforts to market Macau as a destination of choice among international travellers, SJM Resorts, S.A. ("SJM") actively takes part in the Macao Government Tourism Office's ("MGTO") overseas roadshows, as well as its own showcase events aboard. SJM hosted a product seminar last Friday at Waldorf Astoria Bangkok, marking the latest stop in its ongoing "The Legend of Macau" SJM Product Seminar Series following appearances in Shenzhen, Shanghai, Beijing and Taiwan this year. Through the showcase in Thailand, SJM highlighted unique offerings under its portfolio and a lineup of "Tourism+" events it spearheaded. The seminar was met with great enthusiasm, drawing over 100 participants from travel associations, travel agencies, business partners, as well as the MGTO representative in Thailand.

Ms. Daisy Ho, Managing Director of SJM, commented, "Thailand has always been a visitor market of great potential to Macau and is key to expanding its international traveller base. With the latest product seminar, SJM has moved to bolster and expand our connections with the travel trade, MICE planners and business associates in Thailand, through which we could introduce our resort offerings and the multitude of cultural, sports and gastronomy events we have in the pipeline. We sincerely invite our friends from Thailand to experience first-hand the vibrant energy of Macau and the diverse 'Tourism+' allure the city has to offer."

Exclusive Accommodation, Wedding and MICE Offers

At the seminar, SJM outlined the exclusive accommodation, wedding and MICE packages specifically available to Thai travellers. The "Joyous Family Package" and the "Palazzo Versace Macau Experience Package" for Grand Lisboa Palace Macau, THE KARL LAGERFELD MACAU, and the Palazzo Versace Macau are available for booking until 29 December. Reservations made through designated channels before 13 September will receive a complimentary upgrade to a room with a picturesque garden view. Meanwhile, a number of corporate and event planners were eager to learn about the MICE facilities available at the resort that cater to every occasion, and the exclusive rebates, complimentary room, upgrades and more on offer for bookings made before 30 November. Couples looking to tie the knot on or before 31 March 2025, will be entitled to enticing privileges on wedding packages, including Rolls Royce limousine service or a honeymoon trip worth up to MOP63,388.

An All-Star Lineup of SJM

Grand Lisboa Palace Resort Macau, SJM's flagship property, is home to the only international designer-branded hotels in the world. Situated in vibrant Cotai area, its design harmoniously blends Eastern and Western elements, consisting of three magnificent hotel towers: the elegant Grand Lisboa Palace Macau, the one and only THE KARL LAGERFELD MACAU in the world, and the very first Palazzo Versace Macau in Asia. The collection offers ultra-luxurious accommodations, global culinary delights, award-winning spa experiences, fashionable shopping, and exciting happenings, all under one roof.

Likewise, the Grand Lisboa Macau, distinguished with Five-Star ratings from Forbes Travel Guide, is located on the Macau Peninsula and features Robuchon au Dôme, the only restaurant in Macau awarded three MICHELIN Stars for 16 consecutive years. The hotel's restaurants have also garnered MICHELIN Stars, diamonds from the Black Pearl Restaurant Guide, and Wine Spectator awards. Meanwhile, the Jai Alai Oceanus, conveniently connected with the Outer Harbour Ferry terminal, provides a broad spectrum of leisure and entertainment facilities, offering another dimension of guest experience.

At the event, SJM also introduced the long-rooted tourism assets under its parent entity, Sociedade de Turismo e Diversões de Macau, S.A. ("STDM"), which resonate with both heritage and innovation. These include Macau's first five-star Hotel Lisboa, the upscale lifestyle Artyzen Grand Lapa Macau, and the unique beachfront hotel Grand Coloane Resort, as well as the Hotel Sintra, which is only a stone throw away from Macau's UNESCO World Heritage sites. During the event, a lucky draw was also held for attending industry professionals and visitors, allowing them to fully experience the "The Legend of Macau" offerings as curated by SJM and STDM.

Re-defining the Gourmet Experience

Long known as a hub for the region's top fine-dining and MICHELIN-Starred restaurants, SJM has sought to further diversify its dining portfolio by bringing in a host of new establishments this year, including retail stores and cafeterias in collaboration with prestigious global fashion brands, an international cafe that hails from Britain and an Italian family-style diner. As the owner of one of Asia's best wine cellars, SJM is adding to the diversity of gourmet options already available to novelty-seeking visitors, while unlocking new possibilities for Macau as a "Creative City of Gastronomy." This October, SJM is thrilled to partner with Whisky Magazine for the inaugural Whisky Live event at Grand Lisboa Palace. This prestigious international annual celebration will showcase an exquisite selection of whiskies and culinary delights from around the world, creating an unforgettable experience for enthusiasts and connoisseurs alike.

An Extravaganza of Events

In sports and culture, SJM will co-organise and title-sponsor the "SJM 10th Asian Wushu Championships," a showpiece competition featuring elite Chinese martial artists in September. From October to November, SJM will support the "SJM Macao Open 2024," "2024 CTA Tour SJM Professional Finals (Macao) and National Tennis Championships," and the "71st Macau Grand Prix." Under "Art + Tourism," SJM will delight visitors with venues, events and promotions, such as the newly launched artistic hub "GLP Arte" at the Grand Lisboa Palace, the "Dragons of the Four Seas Tribute to Macau" annual Lantern Art Exhibition, and the "Fireworks Cruise Getaway" package for the 32nd Macao International Fireworks Display Contest. Visitors have the opportunity to enjoy the fireworks from an unrivalled vantage point at sea with Macau Cruise.

Going forward, SJM will continue to collaborate with the Macao SAR Government to appeal to Thai tourists by showcasing Macau's diverse "Tourism+" offerings and its multicultural nexus, thereby consolidating its status as a "World Centre of Tourism and Leisure."

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

SJM Showcases Diverse Offerings in Bangkok Product Seminar

SJM Showcases Diverse Offerings in Bangkok Product Seminar

SJM Showcases Diverse Offerings in Bangkok Product Seminar

SJM Showcases Diverse Offerings in Bangkok Product Seminar

SJM Showcases Diverse Offerings in Bangkok Product Seminar

SJM Showcases Diverse Offerings in Bangkok Product Seminar

SHENZHEN, China, Sept. 15, 2024 /PRNewswire/ -- ImmVira announced the latest clinical results for its lead oncolytic virus product, MVR-T3011, via intravesical administration in patients with high-risk BCG-failure non-muscle invasive bladder cancer (NMIBC). The results were published through poster presentation at the 2024 European Society for Medical Oncology (ESMO 2024).

This Phase I, open-label, dose-escalation and expansion study was conducted in China to assess the safety and efficacy of MVR-T3011 administered intravesically in patients with high-risk BCG-failure NMIBC. The study enrolled a broader patient population, including those with high-grade Ta, T1, or CIS +/- Ta/T1 bladder cancer, regardless of the presence of CIS. This inclusive approach aims to target a wider range of patients, potentially accelerating future trial enrollment and expanding market opportunities. The treatment was delivered via intravesical instillation at three dose levels, with weekly induction course lasting 12 weeks, followed by bi-weekly maintenance course for up to one year.

According to poster presented (cut-off as of June 27, 2024), among 14 evaluable patients, the overall 3-month complete response (CR) rate across all dose levels was 71.4% (10/14). At the 2×109 PFU dose level (expected RP2D), the CR rate reached an impressive 87.5% (7/8). The study showed a favorable safety profile, with no dose-limiting toxicities (DLTs) reported and no maximum tolerated dose (MTD) reached. Additionally, MVR-T3011 treatment simplifies clinical procedure by eliminating the need for bladder prewash by nature, further reducing patient discomfort. The instillation process is both quick and efficient.

By September 15, 2024, the most recent data shows that 20 subjects have received MVR-T3011 treatment. At the RP2D dose level, the 3-month CR rate remained strong at 81.8% (9/11). Of the 9 patients who have reached the 6-month assessment, 8 have maintained CR, while 4 patients have reached the 9-month assessment and all remained in CR. We are continuing to gather additional data to support further analysis.

"There is a significant unmet need for innovative treatments for bladder cancer," said Dr. Grace Zhou, Chairwoman and CEO of ImmVira. "We are highly encouraged by the preliminary safety and efficacy data from this Phase I study, especially the 3-month CR rate over 80%, along with durable responses at 6- and 9-month time points. With this early success, we are committed to accelerating clinical development of intravesical MVR-T3011 treatments for BCG-failure NMIBC patients and exploring its potential across other bladder cancer indications. Our goal is to provide a novel, effective, and well-tolerated treatment solution for patients."

About MVR-T3011

MVR-T3011, ImmVira's proprietary 3-in-1 oHSV, is a novel genetic engineered oHSV with advanced backbone design aiming to achieve the most favorable profile of attenuated HSV-1 with replication potency in tumor cells and highly restricted replication in normal cells, supporting intratumoral, intravenous and intravesical administrations. Additionally, MVR-T3011 incorporated two latest and well-validated exogenous genes, PD-1 antibody and IL-12, to further enhance immune responses in the tumor microenvironment.

About ImmVira

ImmVira is a biotechnology company focused on developing and synthesizing biological vector delivery platform. The company has constructed a fully integrated OVPENS® (Open Vector+ Potent, Enabling, Novel & Safe) platform with solid science, technology and CMC know-how, and three derivative subplatforms including Oncolytic Virus, Cancer Vaccine and Biosynthetic Exosome, to support ongoing R&D, clinical studies and commercialization of best-in-class mono and combo therapies driven by clinical benefits in oncology and non-oncology fields.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

ESMO 2024 - ImmVira Unveils Clinical Results of Intravesical MVR-T3011 for High-Risk BCG-Failure NMIBC Patients

ESMO 2024 - ImmVira Unveils Clinical Results of Intravesical MVR-T3011 for High-Risk BCG-Failure NMIBC Patients

ESMO 2024 - ImmVira Unveils Clinical Results of Intravesical MVR-T3011 for High-Risk BCG-Failure NMIBC Patients

ESMO 2024 - ImmVira Unveils Clinical Results of Intravesical MVR-T3011 for High-Risk BCG-Failure NMIBC Patients

ESMO 2024 - ImmVira Unveils Clinical Results of Intravesical MVR-T3011 for High-Risk BCG-Failure NMIBC Patients

ESMO 2024 - ImmVira Unveils Clinical Results of Intravesical MVR-T3011 for High-Risk BCG-Failure NMIBC Patients

Recommended Articles